New York State Teachers Retirement System Buys 15,332 Shares of Edwards Lifesciences Corporation $EW

Key Points

• The New York State Teachers Retirement System increased its stake in Edwards Lifesciences Corporation by 3.5%, acquiring 15,332 shares, bringing its total ownership to 453,606 shares valued at approximately $35.48 million.
• Analysts have mixed opinions on the stock, with JPMorgan Chase raising its target price to $85 and Deutsche Bank adjusting it to $94, while also noting several downgrades from other firms.
• Edwards Lifesciences reported a quarterly earnings per share of $0.67, surpassing expectations, and provided guidance suggesting continued growth with projections for FY 2025 EPS between 2.400 and 2.500.

New York State Teachers Retirement System lifted its stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 3.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 453,606 shares of the medical research company's stock after acquiring an additional 15,332 shares during the period. New York State Teachers Retirement System owned 0.08% of Edwards Lifesciences worth $35,477,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in EW. Brighton Jones LLC bought a new position in shares of Edwards Lifesciences in the 4th quarter worth $266,000. Wealth Enhancement Advisory Services LLC grew its stake in Edwards Lifesciences by 13.5% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 77,016 shares of the medical research company's stock worth $5,582,000 after buying an additional 9,188 shares during the last quarter. Exchange Traded Concepts LLC grew its stake in Edwards Lifesciences by 66.9% during the 1st quarter. Exchange Traded Concepts LLC now owns 21,095 shares of the medical research company's stock worth $1,529,000 after buying an additional 8,453 shares during the last quarter. Wolf Group Capital Advisors purchased a new position in Edwards Lifesciences during the 1st quarter worth $250,000. Finally, State of Alaska Department of Revenue grew its stake in Edwards Lifesciences by 2.7% during the 1st quarter. State of Alaska Department of Revenue now owns 69,069 shares of the medical research company's stock worth $5,006,000 after buying an additional 1,827 shares during the last quarter. 79.46% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. JPMorgan Chase & Co. boosted their target price on Edwards Lifesciences from $80.00 to $85.00 and gave the stock a "neutral" rating in a research note on Friday, July 25th. Deutsche Bank Aktiengesellschaft boosted their target price on Edwards Lifesciences from $85.00 to $94.00 and gave the stock a "buy" rating in a research note on Friday, July 25th. Wall Street Zen downgraded Edwards Lifesciences from a "strong-buy" rating to a "buy" rating in a research note on Monday, September 29th. Truist Financial boosted their target price on Edwards Lifesciences from $81.00 to $82.00 and gave the stock a "hold" rating in a research note on Friday, July 25th. Finally, Oppenheimer downgraded Edwards Lifesciences from an "outperform" rating to a "market perform" rating in a research note on Wednesday, October 8th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences currently has an average rating of "Moderate Buy" and an average target price of $87.06.

Insider Activity

In other news, insider Larry L. Wood sold 8,950 shares of the business's stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the transaction, the insider owned 206,900 shares of the company's stock, valued at $16,150,614. The trade was a 4.15% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of the business's stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the transaction, the vice president directly owned 22,002 shares of the company's stock, valued at approximately $1,748,278.92. This trade represents a 15.75% decrease in their position. The disclosure for this sale can be found here. Insiders own 1.29% of the company's stock.

Edwards Lifesciences Stock Down 0.4%

Edwards Lifesciences stock opened at $72.66 on Friday. The company has a market cap of $42.66 billion, a PE ratio of 10.45, a PEG ratio of 3.50 and a beta of 1.05. The business's 50-day simple moving average is $77.61 and its two-hundred day simple moving average is $76.14. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. Edwards Lifesciences Corporation has a fifty-two week low of $64.89 and a fifty-two week high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.05. The business had revenue of $1.53 billion during the quarter, compared to analysts' expectations of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company's revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Equities analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.